Multicenter Open Label Expanded Access-Program of Pegylated Interferon Alfa-2a (Pegasys) in Patients With Chronic Myelogenous Leukemia (CML)
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Chronic myeloid leukaemia
- Focus Expanded access; Therapeutic Use
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 08 Apr 2016 Status changed from active, no longer recruiting to completed.
- 20 Jun 2006 New trial record.